RACD Stock Forecast: Research Alliance Corp. IV Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 1 Aug 2026 — in the weakest quartile.
RACD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Research Alliance Corp. IV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (75): Smaller than most of the companies we track.
Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Research Alliance Corp. IV — and when they’d sell — is the membership.
RACD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RACD, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RACD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Research Alliance Corp. IV (RACD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- —
- Return on assets
- —
- Dividend yield
- —
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RACD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RACD appears on the weeks it earns a place.
Frequently asked questions about RACD stock
How does Ticker Nerd's model rank RACD?
As at 1 Aug 2026, Research Alliance Corp. IV ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).
What is the RACD stock forecast for 2030?
No analyst covering Research Alliance Corp. IV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RACD are extrapolating price history, which says nothing about the business.
What does Research Alliance Corp. IV do?
Research Alliance Corporation IV is a special purpose acquisition company focused on the healthcare and life sciences sectors. Sponsored by an affiliate of RA Capital Management, the company is organized as a blank check vehicle to carry out a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses.
About Research Alliance Corp. IV.
Research Alliance Corporation IV is a special purpose acquisition company focused on the healthcare and life sciences sectors. Sponsored by an affiliate of RA Capital Management, the company is organized as a blank check vehicle to carry out a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more operating businesses. Its mandate concentrates on healthcare-related industries, with particular emphasis on drug development and commercialization, diagnostics, healthcare technology, and healthcare services, giving it exposure to both biopharmaceutical innovation and enabling healthtech platforms. Headquartered in New York, New York and founded in 2026, Research Alliance Corporation IV operates in the capital markets as an intermediary between institutional and public investors and private or growth-stage healthcare companies seeking access to public market capital and liquidity. Led by an experienced management team with scientific and financial backgrounds, it plays a targeted role in the SPAC segment of the market by sourcing, evaluating, and structuring transactions within the global healthcare and life sciences ecosystem.
CEO Dr. Matthew D. Hammond M.B.A., Ph.D. · United States